United Therapeutics Corp at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Okay, everybody. This is Marty Auster. I'm the lead SMID biotech analyst here at Crédit Suisse. You are joining me today to discuss United Therapeutics at the 29th Annual Crédit Suisse Health Care Conference. I think this is the first time I've had the pleasure of hosting my friends from United Therapeutics at the Health Care Conference.
I've got Mike Benkowitz, the Chief Operating Officer and President of United Therapeutics. And I'm going to pass it over to Dewey Steadman, Head of Investor Relations, to make a few forward-looking statements, and then we'll kind of kickoff some Q&A. Dewey?
Yes. Good Afternoon. Our remarks today may include forward-looking information about our business. Please see our SEC filings for risks and uncertainties that could cause actual results to differ. And thank you. So I'll turn it back over to you, Marty.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |